|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's range||94.87 - 111.99|
|52-week range||21.50 - 111.99|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||13 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||64.18|
Stock markets prepared to continue their downward trend on Wednesday, as early morning moves in futures markets indicated further declines after two losing sessions on Monday and Tuesday. The Nasdaq Composite (NASDAQINDEX: ^IXIC) looked poised to suffer the most significant declines, with futures contracts falling more than 1% in premarket trading. MongoDB (NASDAQ: MDB) rose sharply after the software-as-a-service (SaaS) company reported solid financial results late Tuesday, but the biggest pop came for Prometheus Biosciences (NASDAQ: RXDX).
Shares of Prometheus Biosciences (NASDAQ: RXDX) were down more than 12% this week as of Friday morning, according to data from S&P Global Intelligence. The clinical-stage biotech company specializes in immunotherapies with a focus on inflammatory bowel disease (IBD). Prometheus' lead therapy in its pipeline is IBD drug PRA023.
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -1.12% and 26.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?